On this page
The short answer. Big tech fell more than the rest of the market today, a day before Nvidia’s first results since its chief executive resigned. Index funds that track the Nasdaq 100 and the S&P 500 hold these big tech companies, so a slide in them reaches savers who never picked a single stock.
In the movers table below, the largest gain was CG Oncology, up 13.95% at the 4:00 p.m. ET close, after it said a late-stage bladder cancer trial met its main goal.
Telus rose after it confirmed an unsolicited, non-binding proposal to buy the company. The table below gives each mover’s latest company news, small companies included.
The market at the close, Monday
Every company reporting the same week, with its date and time, is in StockTitan's Earnings Calendar for the Week of November 16, 2026.
Live updates
The newest update comes first, each with the time it was written. Stock and fund moves come from StockTitan data unless another source is named.
8:03 p.m. ET
Closing summary: tech stocks drag the market lower, and Red Cat sinks after hours
Stocks closed lower on Monday, and tech stocks fell the most a day before Nvidia’s results. At the 4:00 p.m. ET close, QQQ, the Nasdaq 100 fund, was down 2.67%, and SPY, the S&P 500 fund, was down 1.91%. At the same close, DIA, the Dow fund, was down 1.43%, and IWM, the small-company fund, was down 1.66%.
The Nasdaq Composite closed down 2.49%, and the S&P 500 closed down 1.92%, CNBC reported. Both indexes fell for a third day in a row, CNBC said. The Dow Jones Industrial Average closed down 1.41%, according to CNBC.
Chip stocks led the drop. At the 4:00 p.m. ET close, Nvidia was down 4.12%, and Micron and Intel were each down more than 7%. A person familiar with the matter told CNBC that Nvidia’s board is not discussing bringing back Jensen Huang as chief executive.
In the movers table, CG Oncology rose the most, up 13.95% at the 4:00 p.m. ET close. The rise came after it said a late-stage bladder cancer trial met its main goal (CG Oncology release). TRexBio fell the most, down 21.21% at the 4:00 p.m. ET close. It had reported third-quarter results after the market closed on November 13 (TRexBio release).
Summit Therapeutics closed down 16.47% at 4:00 p.m. ET. The drop came after Summit said the FDA had issued a complete response letter on its application for ivonescimab with chemotherapy in a form of lung cancer (Summit release). Such a letter means the application cannot be approved in its present form. Telus closed up 12.19% at 4:00 p.m. ET. The rise came after it confirmed an unsolicited, non-binding proposal from Québecor to buy the company (Telus release).
Red Cat was down 26.19% in after-hours trading at 7:59 p.m. ET, against its 4:00 p.m. ET close. The drop came after the drone maker reported third-quarter results and withdrew its full-year 2026 revenue target (Red Cat release). AECOM was up 6.29% at 7:58 p.m. ET, against the same close. It reported fiscal fourth-quarter results, raised its quarterly dividend by 10% and gave its first outlook for fiscal 2027 (AECOM release).
S&P 500, Nasdaq 100 and Dow futures were little changed in evening trading, according to CNBC’s live page, updated at 7:37 p.m. ET. On Tuesday, Disney reports before the open and Nvidia after the close, and What to watch tomorrow gives the times.
6:03 p.m. ET
Red Cat falls and AECOM rises after hours on new results
Two companies that reported after the market closed moved sharply in after-hours trading. Red Cat, a maker of military drones, was down 24.65% at 6:01 p.m. ET against its 4:00 p.m. ET close. The drop came after it reported third-quarter results and withdrew its full-year 2026 revenue target (Red Cat release). The company said funding and contract awards had come more slowly than it expected.
AECOM, an infrastructure design and consulting firm, was up 6.21% at 5:45 p.m. ET. It reported fiscal fourth-quarter results, raised its quarterly dividend by 10% and gave its first outlook for fiscal 2027 (AECOM release).
The final closing prices are now in, and some differ slightly from the last trades before 4:00 p.m. ET. At the 4:00 p.m. ET close, SPY, the S&P 500 fund, was down 1.91%, and DIA, the Dow fund, was down 1.43%. QQQ, the Nasdaq 100 fund, was down 2.67% at the close, and Telus was up 12.19%.
4:03 p.m. ET
Stocks close lower as chip stocks lead the drop before Nvidia’s results
Stocks closed lower on Monday, and tech stocks fell the most. At 4:00 p.m. ET, QQQ, the Nasdaq 100 fund, was down 2.67%, and SPY, the S&P 500 fund, was down 1.90%. DIA, the Dow fund, was down 1.42% at 3:59 p.m. ET.
At the 4:00 p.m. ET close, Nvidia was down 4.12%, while Micron was down 7.62% and Intel 7.02%. Goldman Sachs, Morgan Stanley and JPMorgan Chase were each more than 2% lower at 4:00 p.m. ET.
TRexBio fell 21.21% at the 4:00 p.m. ET close, the largest drop in the movers table. The drug developer reported third-quarter results on November 13 after the market closed, following its October initial public offering (TRexBio release). Summit Therapeutics, the largest drop in our last update, closed down 16.47% at 4:00 p.m. ET. CG Oncology closed up 13.95% at 4:00 p.m. ET, the largest gain in the table.
3:02 p.m. ET
Selling spreads beyond tech stocks to banks
The selling spread beyond tech stocks this afternoon. At 3:01 p.m. ET, QQQ, the Nasdaq 100 fund, was down 2.44%, and SPY, the S&P 500 fund, was down 1.89%. DIA, the Dow fund, was down 1.41%.
Nvidia fell 4.17%, close to its 4.21% drop in our last update. Bank stocks such as Morgan Stanley, Goldman Sachs and JPMorgan Chase were also lower at 3:01 p.m. ET. Consumer staples, the makers of food and household goods, were the only S&P 500 sector that was higher, CNBC said.
The VIX measures how much traders expect the S&P 500 to swing over the next 30 days. It rose as much as 25% to 24.05, its highest level in a week, CNBC reported.
Summit Therapeutics fell 17.31%, now the largest drop in the movers table. The drop came after Summit said the FDA had issued a complete response letter on its application for ivonescimab with chemotherapy in a form of lung cancer (Summit release). Telus rose 11.55%, and Lexeo Therapeutics rose 14.11%, up from 11.11% in our last update.
TRexBio, a drug developer, fell 13.39% at 2:45 p.m. ET. It reported third-quarter results on November 13 after the market closed, following its October initial public offering at $14.00 a share (TRexBio release). Forge Nano’s loss narrowed to 15.69% at 2:56 p.m. ET.
1:02 p.m. ET
Losses deepen as chip stocks fall further
Stocks fell further in the past two hours, and tech still led the drop. At 1:01 p.m. ET, QQQ, the Nasdaq 100 fund, was down 2.33%, and SPY, the S&P 500 fund, was down 1.59%. DIA, the Dow fund, was down 1.02%.
Nvidia fell 4.21%, while Micron fell 6.70% and Intel 6.76%. A person familiar with the matter told CNBC that Nvidia’s board is not discussing bringing back Jensen Huang as chief executive.
CG Oncology rose 16.92%, the largest gain in the movers table. At 8:00 a.m. ET, it said its late-stage PIVOT-006 trial in a form of early bladder cancer met its main goal (CG Oncology release).
Forge Nano, down 14.40% in our last update, fell 19.32% at 1:00 p.m. ET. Lexeo Therapeutics kept a gain of 11.11%, down from 15.64%.
11:03 a.m. ET
Tech losses narrow a little as Summit and Forge Nano slide
Stocks stayed lower, but tech losses narrowed a little. At 11:01 a.m. ET, QQQ, the Nasdaq 100 fund, was down 1.65%, and SPY, the S&P 500 fund, was down 1.02%. Nvidia fell 2.21%. DIA, the Dow fund, was down less, 0.56% at 11:00 a.m. ET.
Summit Therapeutics fell 13.64%. The drop came after Summit said the FDA had issued a complete response letter on its application for ivonescimab with chemotherapy in a form of lung cancer (Summit release). Forge Nano, which makes chip equipment and battery materials, fell 14.40% at 10:59 a.m. ET. It reported third-quarter results, after listing on Nasdaq on October 22 (Forge Nano release).
Lexeo Therapeutics, up 28.22% in our last update, kept a gain of 15.64%. Helus Pharma’s loss narrowed to 8.79% from 19.84%.
10:06 a.m. ET
Stocks open lower as chip stocks lead the drop
Stocks opened lower, and other chip stocks fell more than Nvidia. At 10:01 a.m. ET, QQQ, the Nasdaq 100 fund, was down 1.95%. Micron fell 6.39% and Intel 6.02%, more than Nvidia.
The Commerce Department issued a rule on Monday about remote access to advanced chips. It aims to stop companies from getting around US export limits through data centers in other countries, the department said (Commerce Department release). CNBC reported that the rule targets Chinese companies that lease Nvidia’s computing power from data centers abroad.
Lexeo Therapeutics led the gainers on StockTitan’s movers list, up 28.22%. Helus Pharma, up 3.83% at 9:04 a.m. ET in our last update, turned to a loss of 19.84%. Alpha Tau Medical, down 7.70%, filed the slides from its morning trial call with the SEC (Alpha Tau 6-K). CG Oncology and Telus kept smaller gains than before the open (our Telus article). Tyson Foods rose 9.89% after it reported quarterly results (Tyson release).
9:07 a.m. ET
New York factory growth slows as tech stocks stay lower before the open
Tech stocks stayed lower in the past hour, and a New York factory survey came in below forecasts. The New York Fed’s Empire State index of factory activity fell 18 points to 7.8 in November, a reading that still means growth (New York Fed). Economists had expected 16.7, according to a Dow Jones consensus cited by CNBC. Factory jobs in the state grew at the fastest pace in more than four years, the New York Fed said.
QQQ, the Nasdaq 100 fund, was down 1.31% at 9:04 a.m. ET, and Nvidia was down 3.28%. CG Oncology made the largest move on StockTitan’s pre-market movers list, up 32.26% at 9:04 a.m. ET. At 8:00 a.m. ET, it said its late-stage PIVOT-006 trial in a form of early bladder cancer met its main goal (CG Oncology release). Ballard Power Systems was down 12.87% at 9:02 a.m. ET, after the hydrogen fuel cell maker said its quarterly revenue fell from a year earlier (Ballard release).
Helus Pharma swung back to a gain. It was up 3.83% at 9:04 a.m. ET. Before the open it traded as low as $4.85 and as high as $11.22, against its $8.87 close on November 13. Its depression trial results came out at 7:00 a.m. ET (Helus release).
8:06 a.m. ET
Chip stocks drag tech lower as Nvidia’s results near
The drop in big tech deepened in the past hour. Nasdaq 100 futures were down 1.5% and S&P 500 futures were down 0.7%, according to CNBC’s live page, updated at 7:51 a.m. ET. QQQ, the Nasdaq 100 fund, was down 1.21% at 8:05 a.m. ET, and SPY, the S&P 500 fund, was down 0.56% at 8:04 a.m. ET.
Other chipmakers fell more than Nvidia. By 8:05 a.m. ET, Micron was down 5.59%, Intel 5.20% and AMD 5.15%, while Nvidia was down 2.76%. Over the weekend, Treasury Secretary Scott Bessent urged Nvidia’s board to look outside the company for its next CEO, CNBC reported.
Helus Pharma swung from a gain to a steep loss once its depression trial results were out. It rose 15.45% by 6:40 a.m. ET and was down 30.10% at 8:05 a.m. ET. At 7:00 a.m. ET, Helus said its late-stage APPROACH trial of HLP003 met its main goal (Helus release). Telus was up 26.14% at 8:05 a.m. ET, after the Canadian telecom company confirmed an unsolicited proposal from Québecor to buy it (Telus release). Lexeo Therapeutics was up 23.00%, after it reported early data for its heart disease gene therapy (Lexeo release).
6:45 a.m. ET
Tech stocks slip before the open, with Nvidia’s results a day away
The week starts with big tech under pressure. Nasdaq 100 futures were down 0.79%, a bigger drop than S&P 500 futures, while Dow futures edged up, according to CNBC’s live page, updated at 6:07 a.m. ET. In Asia, chip stocks such as Samsung, SK Hynix and TSMC fell sharply, CNBC said.
SPY, the S&P 500 fund, was down 0.32% at 6:36 a.m. ET, and Nvidia was down 2.55% at 6:41 a.m. ET. Nvidia said on November 12 that Huang had resigned and that finance chief Colette Kress is interim CEO. Its results come on Tuesday, November 17, at about 4:20 p.m. ET (Nvidia release). StockTitan’s article on the CEO change covers Huang’s exit.
Drug developers with fresh news made the largest single moves on StockTitan’s pre-market movers list. Helus Pharma rose 15.45% by 6:40 a.m. ET, before a webcast at 8:00 a.m. ET where it plans to present the main results of a late-stage depression trial (Helus release). By 6:41 a.m. ET, Strategy, a company that holds bitcoin, was down more than 6%. The Coinbase exchange and IBIT, the iShares fund that holds bitcoin, were each down more than 6% too.
Biggest stock movers today and the news behind them
Drug developers with news about their medicines made most of the largest moves in this table. Telus jumped after it confirmed an unsolicited, non-binding proposal to buy the company. Tyson Foods rose after its quarterly results, and Nvidia moved less.
| Company | Move | Company news |
|---|---|---|
| CG Oncology (CGON) | +13.95%, regular-session close, 4:00 p.m. ET | It said its late-stage PIVOT-006 trial of cretostimogene, a drug for a form of early bladder cancer, met its main goal, with a 68% lower risk of the cancer coming back than with monitoring alone after surgery (release). |
| Lexeo Therapeutics (LXEO) | +12.54%, regular-session close, 4:00 p.m. ET | It reported early trial data for its gene therapy LX2020 in an inherited heart disease and said the FDA is open to a heart rhythm measure as the main goal of a trial that could support a faster approval (release). |
| Telus (TU) | +12.19%, regular-session close, 4:00 p.m. ET | The Canadian telecom company said its board received an unsolicited, non-binding proposal from Québecor to buy it, and a board committee is reviewing it while also looking at other options (release). |
| Tyson Foods (TSN) | +8.72%, regular-session close, 4:00 p.m. ET | The food company reported fourth-quarter results, with adjusted earnings per share of $0.61, down 47% from a year earlier, and said it expects sales in its 2027 fiscal year to fall 3.5% to 5.5% (release, results). |
| XPeng (XPEV) | +3.20%, regular-session close, 4:00 p.m. ET | The Chinese carmaker reported third-quarter revenue of RMB24.28 billion (US$3.62 billion), up 19.1% from a year earlier, and expects 169,000 to 174,000 deliveries in the fourth quarter (release). |
| TRexBio (TRXB) | -21.21%, regular-session close, 4:00 p.m. ET | The drug developer reported third-quarter results on November 13 after the market closed, following its October initial public offering at $14.00 a share (release). |
| Forge Nano (NANO) | -16.59%, regular-session close, 4:00 p.m. ET | The chip equipment and battery materials company reported third-quarter results, after listing on Nasdaq on October 22, and said it still expects to reach its 2026 targets (release). |
| Summit Therapeutics (SMMT) | -16.47%, regular-session close, 4:00 p.m. ET | The FDA issued a complete response letter, a rejection in its present form, for ivonescimab with chemotherapy in a form of lung cancer (release). |
| Helus Pharma (HELP) | -13.53%, regular-session close, 4:00 p.m. ET | It said APPROACH, its late-stage trial of HLP003 in major depressive disorder, met its main goal, with depression scores down 7.6 points more than on placebo at six weeks (release). |
| Ballard Power Systems (BLDP) | -10.71%, regular-session close, 4:00 p.m. ET | The hydrogen fuel cell maker said third-quarter revenue fell 31% from a year earlier to $22.5 million, and it is targeting a profit for the full year 2028 (release). |
| Alpha Tau Medical (DRTS) | -10.54%, regular-session close, 4:00 p.m. ET | On Sunday it said all eight patients treated with its Alpha DaRT radiation therapy in a trial for recurring brain cancer were alive as of November 11 (release). |
| Aclaris Therapeutics (ACRS) | -8.04%, regular-session close, 4:00 p.m. ET | Its mid-stage trial of bosakitug in the skin disease atopic dermatitis did not meet its main goal or its secondary goals (release). |
| Nvidia (NVDA) | -4.12%, regular-session close, 4:00 p.m. ET | It said on November 12 that Jensen Huang had resigned as chief executive, and it reports quarterly results on Tuesday, November 17, at about 4:20 p.m. ET (release). |
Source: StockTitan data, against each stock’s November 13 close; company releases linked in each row.
XPeng also posted a third-quarter net loss, wider than a year earlier. Its fourth-quarter delivery outlook would be a rise of about 45% to 50% from a year earlier, the company says (XPeng release).
Why are biotech stocks moving today?
Six drug developers in the table had news about their medicines within the past day. Two were setbacks, and four were trial results the companies call positive. Helus and Alpha Tau, which both reported trial results they call positive, fell after the open.
Summit says its trial met its goal on cancer growth but not on survival. Without a statistically significant gain in overall survival, substantial evidence that the drug works was “not established,” the FDA found, according to Summit. In its trial, ivonescimab with chemotherapy met its goal on how long patients lived without the cancer growing. Summit says survival showed a positive trend that fell short of statistical significance. Summit says its belief in the drug is unchanged and that it is testing it in other cancers (Summit release, 8-K).
CG Oncology says its bladder cancer drug cut the risk of the cancer coming back. Its PIVOT-006 trial enrolled 367 patients after surgery removed their tumors. Their cancer had not grown into the bladder muscle. Patients given cretostimogene had a 68% lower risk of the cancer returning than patients who were only monitored, the company said. The company reported no treatment-related side effects rated grade 3 or higher, the severe end of the scale. CG Oncology plans to complete its request for FDA approval in these patients in the second quarter of 2027 (CG Oncology release).
Helus says its trial met its main goal, and the stock swung back to a loss after the open. The APPROACH trial enrolled 223 adults whose depression did not respond enough to their current antidepressant (Helus quarterly release). After six weeks, scores on a standard depression scale fell 19.5 points with HLP003 and 11.9 points with placebo, Helus said. It also reported three serious side effects related to the drug, and said no new safety signals were found (Helus results release).
HLP003 has the FDA’s Breakthrough Therapy designation, which the FDA says is meant to speed the development and review of drugs for serious conditions when early clinical evidence suggests a substantial improvement (FDA). Helus ended September with $171.1 million in cash, it said in its quarterly results (Helus quarterly release).
Alpha Tau’s update came from a small early trial. Five of the six patients assessed so far had a complete response, with no measurable tumor left at the treated site. The company also says scans in some patients show tissue damage from radiation, and that in two of them it cannot yet tell that from tumor growth (Alpha Tau release). Aclaris says the atopic dermatitis result does not change its plans, which center on its other drugs. The same morning it said it had started a mid-stage trial of modzatinib in the inflammatory disease lichen planus (Aclaris release).
Lexeo’s data came from ten patients with PKP2 arrhythmogenic cardiomyopathy, an inherited disease of the heart muscle. Among the seven patients given the high dose, brief episodes of a very fast heartbeat fell 80% on average, Lexeo said. It also said the FDA is open to using those bursts as the main goal of a larger trial that could support a faster approval (Lexeo release).
What to watch tomorrow
On Tuesday, November 17, US retail sales come out at 8:30 a.m. ET (New York Fed calendar). Disney reports before the open, and Nvidia reports after the close.
What to watch
- How much US shoppers are spending: the Advance Retail Sales report on Tuesday, November 17, at 8:30 a.m. ET, per the New York Fed calendar. The same calendar lists import and export prices at 8:30 a.m. ET and industrial production at 9:15 a.m. ET.
- What Disney reports for its fiscal fourth quarter: results at about 6:30 a.m. ET and a webcast at 8:30 a.m. ET, per its November 16 release.
- What Nvidia reports for the quarter: its results release on Tuesday, November 17, at about 4:20 p.m. ET, per its November 12 release.
Our numbers
These figures are our calculations from the sources linked in this article.
- Nvidia about 10% below its last close before Huang resigned: the $156.14 close at 4:00 p.m. ET on November 16 against the $173.73 close of Wednesday, November 11, in StockTitan data; Nvidia announced the resignation before the open on November 12.
- Each move on this page: the last trade or close at the time shown against the stock’s or fund’s November 13 close in StockTitan data. After-hours moves compare with the November 16 regular-session close instead.
Frequently asked questions
On November 16, 2026, tech stocks pulled the market lower as traders reacted to more news about Nvidia a day before its results, CNBC reported. At the 4:00 p.m. ET close, QQQ, the Nasdaq 100 fund, was down 2.67%, and SPY, the S&P 500 fund, was down 1.91%. Chip stocks such as Micron and Intel closed down more than Nvidia, and big banks such as Goldman Sachs were lower too. In the movers table on this page, CG Oncology had the largest gain and TRexBio the largest drop, while Summit Therapeutics and Telus also made big moves, each with fresh company news.
Summit closed down 16.47% at 4:00 p.m. ET on November 16, 2026, in regular trading. The drop came a day after Summit said the FDA had issued a complete response letter on its application for ivonescimab with chemotherapy in a form of lung cancer, meaning that application cannot be approved in its present form. The FDA said substantial evidence of effectiveness was not established without a statistically significant survival gain, according to Summit.
CG Oncology closed up 13.95% at 4:00 p.m. ET on November 16, 2026, in regular trading, a smaller gain than before the open. The rise came after it said at 8:00 a.m. ET that its late-stage PIVOT-006 trial of cretostimogene in bladder cancer met its main goal, with a 68% lower risk of the cancer coming back than with monitoring alone.
Helus closed down 13.53% at 4:00 p.m. ET on November 16, 2026, in regular trading. Before the open, it had traded both above and below its November 13 close. The fall came on the day it said at 7:00 a.m. ET that its late-stage APPROACH trial of HLP003 in depression met its main goal, with scores down 7.6 points more than on placebo at six weeks. It also reported three serious side effects related to the drug.
Lexeo closed up 12.54% at 4:00 p.m. ET on November 16, 2026, in regular trading. The rise came after it reported early trial data for its gene therapy LX2020 in an inherited heart disease, and said the FDA is open to a heart rhythm measure as the main goal of a trial that could support a faster approval.
Telus closed up 12.19% at 4:00 p.m. ET on November 16, 2026, in regular trading. The rise came after it confirmed an unsolicited, non-binding proposal from Québecor to buy the company. Telus said a committee of independent directors is reviewing it and has found significant regulatory and execution risks.
Aclaris closed down 8.04% at 4:00 p.m. ET on November 16, 2026, in regular trading. The drop came after it said its mid-stage ADMIRATION trial of bosakitug in the skin disease atopic dermatitis did not meet its main goal or its secondary goals. Aclaris says the result does not change its plans, which center on its other drugs.
Nvidia closed down 4.12% at 4:00 p.m. ET on November 16, 2026, in regular trading, leaving it about 10% below its November 11 close, the last before it said Jensen Huang had resigned. Nvidia reports quarterly results on Tuesday, November 17, at about 4:20 p.m. ET.
Sources
- StockTitan Earnings Calendar, week of November 16, 2026
- StockTitan, Nvidia CEO change
- Summit Therapeutics ivonescimab BLA update
- Summit Therapeutics Form 8-K, November 16, 2026
- Helus Pharma APPROACH webcast notice
- Helus Pharma second quarter fiscal 2027 results
- Helus Pharma APPROACH topline results
- Telus statement on the Québecor proposal
- Lexeo Therapeutics LX2020 interim data
- Alpha Tau REGAIN interim results
- Aclaris ADMIRATION trial results
- Aclaris modzatinib Phase 2b trial start
- XPeng third quarter 2026 results
- CG Oncology PIVOT-006 topline results
- Ballard third quarter 2026 results
- Nvidia CEO transition
- Forge Nano third quarter 2026 results
- FDA, Breakthrough Therapy
- New York Fed, Empire State Manufacturing Survey
- New York Fed, economic indicators calendar
- Commerce Department, Bureau of Industry and Security, rule on remote access to advanced chips
- Tyson Foods fourth quarter and fiscal 2026 results notice
- Tyson Foods fourth quarter and fiscal 2026 earnings release, SEC exhibit
- Alpha Tau Form 6-K, November 16, 2026
- StockTitan, Telus and the Québecor proposal
- TRexBio third quarter 2026 results
- Red Cat third quarter 2026 results
- AECOM fourth quarter and fiscal 2026 results
- Disney results timing notice